If the business delivers 40M revenues and 15M EBITDA for FY21, that implies a ~6x sales and ~15x EBITDA valuation; which is certainly not expensive given the earnings momentum. Clearly they have been a beneficiary from COVID - my only question would be what happens when a vaccine is found? Would we see revenue and earnings drop to previous years?
If the business delivers 40M revenues and 15M EBITDA for FY21,...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $181.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 80.0¢ | 77.0¢ | $307.5K | 390.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 78.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.0¢ | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| GSS (ASX) Chart |